These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23429386)

  • 1. Radioiodine therapy for Graves disease: thyroid absorbed dose of 300 Gy-tuning the target for therapy planning.
    Willegaignon J; Sapienza MT; Buchpiguel CA
    Clin Nucl Med; 2013 Apr; 38(4):231-6. PubMed ID: 23429386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Graves' disease radioiodine-therapy: choosing target absorbed doses for therapy planning.
    Willegaignon J; Sapienza MT; Coura-Filho GB; Watanabe T; Traino AC; Buchpiguel CA
    Med Phys; 2014 Jan; 41(1):012503. PubMed ID: 24387527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism.
    Grosso M; Traino A; Boni G; Banti E; Della Porta M; Manca G; Volterrani D; Chiacchio S; AlSharif A; Borsò E; Raschillà R; Di Martino F; Mariani G
    Cancer Biother Radiopharm; 2005 Apr; 20(2):218-23. PubMed ID: 15869459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalization of radioiodine treatment for Graves' disease: a prospective, randomized study with a novel method for calculating the optimal 131I-iodide activity based on target reduction of thyroid mass.
    Orsini F; Traino AC; Grosso M; Guidoccio F; Boni G; Volterrani D; Mariani G
    Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):496-502. PubMed ID: 23358401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome.
    Reinhardt MJ; Brink I; Joe AY; Von Mallek D; Ezziddin S; Palmedo H; Krause TM
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1118-24. PubMed ID: 12192554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maximum dose rate is a determinant of hypothyroidism after 131I therapy of Graves' disease but the total thyroid absorbed dose is not.
    Krohn T; Hänscheid H; Müller B; Behrendt FF; Heinzel A; Mottaghy FM; Verburg FA
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4109-15. PubMed ID: 25033065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dosimetric approach to patient-specific radioiodine treatment of Graves' disease with incorporation of treatment-induced changes in thyroid mass.
    Traino AC; Di Martino F; Lazzeri M
    Med Phys; 2004 Jul; 31(7):2121-7. PubMed ID: 15305466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possibility of limiting the un-justified irradiation in (131)I therapy of Graves' disease: a thyroid mass-reduction based method for the optimum activity calculation.
    Traino AC; Grosso M; Mariani G
    Phys Med; 2010 Apr; 26(2):71-9. PubMed ID: 19800827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
    Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
    Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid echogenicity: A clue to precise individual dosimetry in radioiodine therapy of hyperthyroidism.
    Marković V; Eterović D; Stipanović P; Punda A
    Med Hypotheses; 2011 Feb; 76(2):153-6. PubMed ID: 20889262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High failure rates after (131)I therapy in Graves hyperthyroidism patients with large thyroid volumes, high iodine uptake, and high iodine turnover.
    de Jong JA; Verkooijen HM; Valk GD; Zelissen PM; de Keizer B
    Clin Nucl Med; 2013 Jun; 38(6):401-6. PubMed ID: 23579983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
    Howarth D; Epstein M; Lan L; Tan P; Booker J
    Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation.
    Jentzen W; Moldovan AS; Ruhlmann M; Görges R; Bockisch A; Rosenbaum-Krumme S
    Nuklearmedizin; 2015; 54(3):137-43. PubMed ID: 25987357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Verification of the agreement of two dosimetric methods with radioiodine therapy in hyperthyroid patients.
    Canzi C; Zito F; Voltini F; Reschini E; Gerundini P
    Med Phys; 2006 Aug; 33(8):2860-7. PubMed ID: 16964862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
    Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
    J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Planning of 131I therapy for graves disease based on the radiation dose to thyroid follicular cells.
    Eterovic D; Antunovic Z; Markovic V; Grosev D
    J Nucl Med; 2008 Dec; 49(12):2026-30. PubMed ID: 18997041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?
    Eschner W; Kobe C; Schicha H
    Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioiodine therapy for Graves' disease - retrospective analysis of efficacy factors.
    Szumowski P; Abdelrazek S; Kociura Sawicka A; Mojsak M; Kostecki J; Sykała M; Myśliwiec J
    Endokrynol Pol; 2015; 66(2):126-31. PubMed ID: 25931042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule.
    Sgouros G; Song H; Ladenson PW; Wahl RL
    J Nucl Med; 2006 Dec; 47(12):1977-84. PubMed ID: 17138740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of the possibility of curing Graves' disease based on the desired reduction of thyroid mass (volume) as a consequence of 131I therapy: a speculative paper.
    Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
    Nucl Med Commun; 2006 May; 27(5):439-46. PubMed ID: 16609355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.